Serelaksin: novaya nadezhda na revolyutsionnyy proryv v lechenii ostroy serdechnoy nedostatochnosti


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article discusses the results of studies of drugs for the treatment of acute heart failure (AHF). The focus is on drug serelaxin (recombinant analogue of human relaxin-2), which is a promising drug for first-line treatment of AHF, allows to relief symptoms and improve clinical outcomes. Results of the study were the basis for assigning the expedited review status for registration of serelaxin in the Food and Drug Administration.

全文:

受限制的访问

作者简介

E. Ushkalova

Email: eushk@yandex.ru

参考

  1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220.
  2. Maggioni AP, Dahlstrm U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-year followoults of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15(7):808-17.
  3. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
  4. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the sub-Saharan Africa survey of heart failure. Arch Intern Med 2012;172( 18): 1386-94.
  5. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36.
  6. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381(9860):29-39.
  7. Link A, Poss J, Bohm M. [Pharmacotherapy of acute heart failure: update and perspectives]. Dtsch Med Wochenschr 2012;137(21): 1126-29.
  8. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIMECHF study. J Am Coll Cardiol 2003;41:997-1003.
  9. Packer M., Colucci W., Fisher L., et al. Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure. J Am Coll Cardiol HF 2013;1:103-11.
  10. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial JAMA 2007;297(17):1883-91.
  11. Sackner-Bernstein JD, KowalskiM, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. J Am Med Assoc 2005;293:1900-905.
  12. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365(1):32-43.
  13. Bathgate RA, Halls ML, van der Westhuizen ET, et al. Relaxin family peptides and their receptors. Physiol Rev 2013;93(1 ):405-80.
  14. Jeyabalan A, Shroff SG, Novak J, Conrad KP. The vascular actions of relaxin. Adv Exp Med Biol 2007;612:65-87.
  15. Debrah DO, Conrad KP, Jeyabalan A, Danielson LA, Shroff SG. Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 2005;46(4):745-50.
  16. Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 2011 ;301(2):267-75.
  17. Ezekowitz JA. Novel pharmacologic therapies in development for acute decompensated heart failure. Curr Cardiol Rep 2013;15(2):329.
  18. Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009; 14(4):321 -29.
  19. Danielson LA, Conrad KP. Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. J Clin Invest 1995;96(1):482-90.
  20. Debrah DO, Conrad KP, et al. (2005) Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response. J Appl Physiol 98:1013-20.
  21. Palejwala S, Tseng L. et al. Relaxin gene and protein expression and its regulation of procollagenase and vascular endothelial growth factor in human endometrial cells. Biol Reprod 2002;66(6): 1743-48.
  22. Toth M, Taskinen P, et al. Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart. J Endocrinol 1996;150(3):487-95.
  23. Unemori EN, Erikson ME, et al. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum Reprod (Oxford, England) 1999;14(3):800-6.
  24. Dschietzig T, Unemori E, et al. A pilot safety, tolerability and pharmacodynamic trial of intravenous recombinant human relaxin in compensated heart failure. J Card Fail 2009; 15(3): 182-90.
  25. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase Ilb study. Lancet 2009;373(9673): 1429-39.
  26. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013 Jan 15;61(2):196-206.
  27. RELAX-AHF: Serelaxin Reduces Dyspnea, But Questions Surround Mortality Benefit. Medscape. Nov 06, 2012 http://www.medscape.com/view-article/774039

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##